摘要
目的:探讨国产利福昔明治疗急性细菌性肠道感染的有效性和安全性。方法:按照系统评价的要求,全面检索了1994年1月-2008年12月中国医院数字图书馆、中文科技期刊数据库,对符合纳入标准的l5篇文献共计2443名患者的相关疗效指标进行了Meta分析。结果:与环丙沙星、左氧氟沙星相比,国产利福昔明治疗急性细菌性肠道感染的痊愈率、有效率、细菌清除率差异均无统计学意义(P>0.05);国产利福昔明不良反应发生率为3.29%(39/1184),与对照药物比较差异无统计学意义[OR合并=0.93,95%CI为0.60～1.44,P=0.74]。结论:目前国内证据表明,与环丙沙星、左氧氟沙星相比,国产利福昔明治疗急性细菌性肠道感染疗效无显著性差异。
Objective：To estimate the efficacy and safety of indigenous rifaximin in the treatment of acute infectious diarrhea. Methods： Based on the principles and methods of systematic reviews, we searched Chinese Hospital Digital Database and VIP from January 1994 to December 2008. Meta-analysis was performed on the related clinical indexes of 2443 patients involved in 15 papers which met the inclusion criteria. Results： The clinical cure rates, clinical effective rates, corresponding bacterial eradication rates of indigenous rifaximin showed no significant difference compared with ciprofioxacin and levofloxacin （P〉0.05）. ADR incidence rate of indigenous rifaximin was 3.29% （39/1184）, and there was no significant difference compared with control drugs （OR emerging 0.93, 95%CI 0.60-1.44, P=0.74）. Conclusion： According to the domestic evidence, indigenous rifaximin was effective and safe in the treatment of acute infectious diarrhea compared with ciprofloxacin and levo？oxacin.
出处
《中国药物应用与监测》
CAS
2010年第2期76-79,共4页
Chinese Journal of Drug Application and Monitoring
